Unsere Publikationen

Real-world patient characteristics, treatment patterns and costs in relapsing multiple sclerosis patients treated with glatiramer acetate, dimethyl fumarate or teriflunomide in Germany

Link
https://doi.org/10.2217/nmt-2021-0031
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Ziemssen T, Kurzeja A, Muresan B, Haas JS, Alexander J, Driessen MT.
Verlag
Neurodegenerative Dis Manage 2022;12(2):93-107.
Zum Eintrag

Safety, Adherence and Persistence in a Real-World Cohort of German MS Patients Newly Treated With Ocrelizumab: First Insights From the CONFIDENCE Study

Link
https://doi.org/10.3389/fneur.2022.863105
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Weber MS, Buttmann M, Meuth SG, Dirks P, Muros-Le Rouzic E, Eggebrecht JC, Hieke-Schulz S, Leemhuis J, Ziemssen T.
Verlag
Front Neurol. 2022 May 9;13:863105.
Zum Eintrag

Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany

Link
https://doi.org/10.1007/s00415-021-10931-w
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Ziemssen T, Lang M, Schmidt S, Albrecht H, Klotz L, Haas J, Lassek C, Lang S, Winkelmann VE, Ettle B, Schulze-Topphoff U; PANGAEA study group.
Verlag
J Neurol. 2022 Jun;269(6):3276-3285.
Zum Eintrag

Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart® Injector: Results of the Prospective Cohort Study REBIFLECT

Link
https://doi.org/10.1007/s12325-022-02100-w
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Rieckmann P, Ziemssen T, Penner IK, Raji A, Wagner T, Richter J, Zettl UK.
Verlag
Adv Ther. 2022 Jun;39(6):2749-2760.
Zum Eintrag

OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany

Link
https://doi.org/10.3389/fneur.2022.913616
Tags
Multiple SkleroseMS BehandlungManagement & Science
Jahr
2022
Autoren
Ziemssen T, Richter S, Mäurer M, Buttmann M, Kreusel B, Poehler AM, Lampl M, Linker RA.
Verlag
Front Neurol. 2022 Jun 27;13:913616.
Zum Eintrag

Evaluation of the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis from a societal perspective in Germany

Link
https://doi.org/10.1177/20552173221085741
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Koeditz D, Frensch J, Bierbaum M, Ness N-, Ettle B, Ziemssen T.
Verlag
Nervenheilkunde 2022;41(7-8):502-508.
Zum Eintrag

Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety

Link
https://doi.org/10.1007/s10354-022-00931-4
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Moser T, Ziemssen T, Sellner J.
Verlag
Wien Med Wochenschr 2022;172(15-16):365-372.
Zum Eintrag

Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients

Link
https://doi.org/10.3390/ijms232213759
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Akgün K, Behrens J, Schriefer D, Ziemssen T.
Verlag
Int J Mol Sci 2022;23(22).
Zum Eintrag
3 4 5 6 7

Publikationen durchsuchen

Publikationen filtern

Filters
Tags
Multiple Sklerose
MS Behandlung
Mobilität
Autonomes Nervensystem & Neuroendokrinologie
Neuroimmunologie
Herzratenvariabilität
Baroreflexsensitivität
Management & Science
eHealth
Gesundheitsökonomie
Andere
Show AllHide
Jahr
-